Real World Evidence of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis RFP
Academic Unit: inquire with unit
Memorial Deadline: Monday 8th, January 2024
External Deadline: Thursday 11th, January 2024
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: October 23, 2023
Geographic Scope: Global; all countries where abrocitinib is approved.
Clinical Area: Atopic Dermatitis
Application Due Date: January 11, 2024
Specific Area of Interest: Potential applicants are encouraged to develop retrospective general research studies for abrocitinib in the management of atopic dermatitis (AD) resuting in RWE and publication of these results. The grant can be used for conducting a retrospective chart review analysis, and/or medical writing support.